<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017926</url>
  </required_header>
  <id_info>
    <org_study_id>A6781002</org_study_id>
    <nct_id>NCT01017926</nct_id>
  </id_info>
  <brief_title>Triazolam Trial In Healthy Subjects To Compare Bioavailability Between Formulations Of Triazolam To Determine Their Bioequivalence In Terms Of Rate And Magnitude Of Absorption</brief_title>
  <official_title>An Open, Two Period, Two Treatment, Two Sequence, Crossed, Randomized, Single-Dose Study Of Two Oral Preparations Containing 0.25 Mg Of Triazolam (Halcion, Pharmacia &amp; Upjohn S.A. De C.V. Vs. Product Made By Pfizer Pharmaceuticals LLC) In Healthy Volunteers Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Investigación Farmacológica y Biofarmacéutica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the bioavailability of two oral formulations of&#xD;
      Triazolam in healthy volunteers, in order to determine that they are bioequivalent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The bioequivalence trial of triazolam is due to change in manufacture site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">September 2010</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish Cmax, Tmax, elimination half life, area below the curve from zero to t, and area below the curve from zero to infinity (ABC 0-∞) of the two formulations of Triazolam in tablets</measure>
    <time_frame>Day 1 and two after dosage is taken</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Statistically compare the bioavailability of the pharmaceutical formulations of Triazolam studied, to establish or rule out the existence of bioequivalence</measure>
    <time_frame>Six to eight weeks after completing the study, a final report will be prepared.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the safety of both preparations based on the record of adverse events on completing both study periods</measure>
    <time_frame>Up to 3 days after the 2nd period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Triazolam Reference Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>There will be a clearance period of at least 3 days between the two phases of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triazolam Trial Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triazolam</intervention_name>
    <description>Tablets, 0.25 mg, single-dose, 1 period of 3 three days.</description>
    <arm_group_label>Triazolam Reference Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triazolam</intervention_name>
    <description>Tablets, 0.25 mg, single-dose, 1 period of 3 three days.</description>
    <arm_group_label>Triazolam Trial Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only healthy volunteers, between the ages of 18 and 40 years, will be included.&#xD;
&#xD;
          -  Subjects' body mass index must be between 19-27.&#xD;
&#xD;
          -  Volunteers must be in good health, as determined by the results of a complete clinical&#xD;
             history prepared by doctors at the clinical research site and laboratory tests&#xD;
             performed at certified clinical laboratories.&#xD;
&#xD;
          -  Volunteers must agree to use at least two birth control methods (except hormonal&#xD;
             contraceptives) from the first dose of the study drug and for up to 28 days after the&#xD;
             last dose. (acceptable methods are surgically definitive sterilization, menopause,&#xD;
             barrier methods such as condoms and diaphragm, and spermicidal gels/foams)&#xD;
&#xD;
          -  The limits of variation permitted within normality at the screening visit will be:&#xD;
             blood pressure (seated) 90 to 130 mm Hg systolic and 60 to 90 mm Hg diastolic, heart&#xD;
             rate between 55 and 100 beats per minute and respiratory rate between 14 and 20&#xD;
             respirations per minute.&#xD;
&#xD;
          -  The laboratory and cabinet tests required to include subjects in the studio will be:&#xD;
             1) Hematology: hemoglobin, hematocrit, total white blood cell count with differential,&#xD;
             and platelet count, 2) 27-element blood chemistry, 3) Markers for hepatitis B and C.&#xD;
             4) Detection of HIV, 5) General urinalysis, 6) Drug abuse test in both study periods,&#xD;
             7) Qualitative pregnancy test in both study periods (if applicable) , 8)&#xD;
             Electrocardiogram. (pre-screening/recruitment)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects in whom any alteration is detected in their vital signs recorded at the&#xD;
             screening of volunteers.&#xD;
&#xD;
          -  Volunteers who fail to comply with the established criteria for inclusion.&#xD;
&#xD;
          -  Volunteers with antecedents of cardiovascular, renal, hepatic, muscular, metabolic,&#xD;
             and gastrointestinal disorders, including constipation; neurological, endocrine, and&#xD;
             hematopoietic disorders; or any kind of anemia, asthma, mental illness, or other&#xD;
             organic abnormalities, as well as those who have suffered a muscular traumatism within&#xD;
             21 days before the study.&#xD;
&#xD;
          -  Volunteers who require any medication over the course of the study, aside from the&#xD;
             drug being studied.&#xD;
&#xD;
          -  Volunteers with antecedents of dyspepsia, gastritis, esophagitis, and duodenal or&#xD;
             gastric ulcers.&#xD;
&#xD;
          -  Volunteers who have been exposed to known hepatic enzyme inductors or inhibitors or&#xD;
             have taken potentially toxic drugs within 30 days before the start of the study.&#xD;
&#xD;
          -  Volunteers who have received any medication within 14 days or 5 half lives (whichever&#xD;
             is longer) before the start of the study.&#xD;
&#xD;
          -  Volunteers who have been hospitalized for any problem within seven months before the&#xD;
             start of the study.&#xD;
&#xD;
          -  Subjects who have received investigational drugs within 60 days prior to the study.&#xD;
&#xD;
          -  Subjects allergic to any antibiotic and/or non-steroidal antiinflammatory analgesics.&#xD;
&#xD;
          -  Subjects who have consumed alcohol or xanthine containing beverages (coffee, tea,&#xD;
             cocoa, chocolate, mate, colas) or have consumed charcoal broiled foods or grapefruit&#xD;
             juice within one week before the start of the study and until the last sample is&#xD;
             taken.&#xD;
&#xD;
          -  Subjects who have donated or lost 450 mL or more of blood within 60 days before the&#xD;
             start of the study.&#xD;
&#xD;
          -  History of regular consumption of alcohol exceeding 14 drinks/week (1 drink = 5 ounces&#xD;
             (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of liquor within&#xD;
             6 months before the screening visit.&#xD;
&#xD;
          -  Excessive use of products containing tobacco or nicotine, equivalent to 5 cigarettes&#xD;
             per day.&#xD;
&#xD;
          -  Female volunteers with positive results on the pregnancy test or in lactation.&#xD;
&#xD;
          -  Volunteers who require a special diet for any reason, for example vegetarians.&#xD;
&#xD;
          -  Disability of any kind that prevents the volunteer from understanding the nature,&#xD;
             purpose, and potential consequences of the study.&#xD;
&#xD;
          -  Evidence of an uncooperative attitude during the study.&#xD;
&#xD;
          -  Female volunteers in lactation.&#xD;
&#xD;
          -  Female volunteers who receive oral contraceptives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6781002</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Triazolam bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

